导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.73% | 1184/3712 |
| 近一周 | -1.20% | 1361/4228 |
| 近一月 | -8.20% | 3728/4196 |
| 近一季 | -18.19% | 3624/4044 |
| 近半年 | -0.69% | 1210/3824 |
| 近一年 | 7.74% | 1098/3446 |
| 近两年 | 112.19% | 411/2399 |
| 近三年 | 67.31% | 302/1802 |
| 成立以来 | 119.81% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.86% 1992/4961 |
34.96% 935/5312 |
- - |
- - |
| 2025 | 49.27% 488/4813 |
-1.45% 2668/3635 |
3.27% 1075/4076 |
47.90% 419/4524 |
-0.83% 2670/4813 |
| 2024 | 13.99% 1084/3463 |
-3.52% 1516/2808 |
-6.20% 1881/3014 |
27.76% 209/3129 |
-1.41% 1694/3463 |
| 2023 | -17.31% 1729/2656 |
2.17% 1422/2280 |
-6.64% 1678/2385 |
-8.44% 1700/2515 |
-5.32% 1320/2655 |
| 2022 | -27.12% 1456/2207 |
-18.63% 1364/1919 |
5.64% 854/2016 |
-17.24% 1568/2113 |
2.46% 929/2208 |
| 2021 | 17.19% 242/1822 |
-4.27% 854/1255 |
25.89% 82/1330 |
-5.37% 800/1466 |
2.76% 525/1822 |
| 2020 | 69.00% 80/1250 |
4.90% 58/1028 |
29.29% 80/1067 |
7.95% 752/1164 |
15.43% 206/1184 |
| 2019 | - - |
- - |
- - |
- - |
9.64% 214/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 永赢创业板指数发起式C VS. 长安沪深300非周期A(740101) |